Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles - BioSpace

[anonymous]

Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles - BioSpace

https://www.biospace.com/drug-devel...-in-doubt-as-newly-approved-drugs-hit-hurdles

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of these anti-amyloid antibodies and the amyloid hypothesis overall.​

 

[anonymous]

The benefit is questionable. The danger is real. “These approaches have not worked,” George Perry, a neuroscientist at the University of Texas at San Antonio, told BioSpace, referring to Biogen and Eisai’s Aduhelm and Leqembi and Eli Lilly’s Kisunla. “The patients are not getting better.” Christian Hölscher, co-founder and chief scientific officer at neuroscience-focused Kariya Pharmaceuticals, agreed, raising concerns in a November interview about the drugs’ safety and efficacy profiles. “The antibodies are too toxic, and the effect in patients is so small that it is unlikely that patients even notice a difference,” he told BioSpace.

 

[anonymous]

I like a therapy that might actually do something and doesn’t have the potential to kill me. I’m funny that way.

 

[anonymous]

Pray for the Japs.

 

[anonymous]

Alex Scott did the dude.

 

[anonymous]

So much for that whole blockbuster thing. The situation won’t improve either when reports of fatal brain bleeds start to become public.

 

[anonymous]

So much for that whole blockbuster thing. The situation won’t improve either when reports of fatal brain bleeds start to become public.

I think you’re looking for the Kisunla board.

 

[anonymous]

I think you’re looking for the Kisunla board.

Stay tuned. The Leqembi days are over. Your company is sketchy to say the very least.